Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT06174402

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis

Status
Active Not Recruiting
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
184 (estimated)
Sponsor
Han Ying · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (PBC)

Conditions

Interventions

TypeNameDescription
DRUGFenofibrateFenofibrate 200 mg/day
DRUGPlacebo1 tablet/ day
DRUGUDCAUDCA 13-15mg/kg/day

Timeline

Start date
2023-08-21
Primary completion
2026-07-01
Completion
2026-12-31
First posted
2023-12-18
Last updated
2026-01-08

Locations

10 sites across 1 country: China

Source: ClinicalTrials.gov record NCT06174402. Inclusion in this directory is not an endorsement.

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis (NCT06174402) · Clinical Trials Directory